IGF Level in Breast Cancer Patients Treated With Metformin
NCT ID: NCT05840068
Last Updated: 2023-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
107 participants
INTERVENTIONAL
2020-06-01
2021-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.
NCT04387630
Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)
NCT04170465
Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients
NCT00909506
Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions
NCT03685409
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions
NCT03684707
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metformin and Chemotherapy
Metformin (500 mg twice daily) plus chemotherapy is administered to Group A (n=57)
MetFORMIN 500 Mg Oral Tablet
MetFORMIN 500 Mg Oral Tablet
Chemotherapy
The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).
Chemotherapy alone
Chemotherapy is administered alone to Group B (n=50).
Chemotherapy
The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MetFORMIN 500 Mg Oral Tablet
MetFORMIN 500 Mg Oral Tablet
Chemotherapy
The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients older than 18
* nondiabetic patients
* patients who received only chemotherapy
Exclusion Criteria
* patients receiving hormonal therapy or radiotherapy
* patients with diabetes
* history of cardiac diseases
* hypersensitivity, or allergy to metformin.
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beni-Suef University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marian S. Boshra
Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Marian S. Boshra
Banī Suwayf, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ko KP, Ma SH, Yang JJ, Hwang Y, Ahn C, Cho YM, Noh DY, Park BJ, Han W, Park SK. Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat. 2015 Sep;153(2):361-70. doi: 10.1007/s10549-015-3519-8. Epub 2015 Aug 21.
Essa NM, Salem HF, Elgendy MO, Gabr A, Omran MM, Hassan NA, Tashkandi HM, Harakeh S, Boshra MS. Efficacy of Metformin as Adjuvant Therapy in Metastatic Breast Cancer Treatment. J Clin Med. 2022 Sep 20;11(19):5505. doi: 10.3390/jcm11195505.
Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008 Dec;8(12):915-28. doi: 10.1038/nrc2536.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IGF level in breast cancer
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.